How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work

Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.

By Alexandra Pecci • March 27, 2023

What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

How life science execs would transform clinical trials with a little hocus pocus.

By PharmaVoice staff • March 24, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Everyone says they’re patient-centric, but have they really walked the walk?

Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

By Karissa Waddick • March 23, 2023

Woman of the Week: RIGImmune’s Susan Sobolov

RIGImmune’s president is setting her sights on an off-the-shelf viral vaccine.

By Taren Grom • March 22, 2023

Making the leap from the lab to the boardroom

Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.

By Alexandra Pecci • March 21, 2023

A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

By Michael Gibney • March 16, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023

The power of connections for a startup CEO

Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

By Alexandra Pecci • March 14, 2023

Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

Woman of the Week: Lucy Therapeutics’ Amy Ripka

How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

By Taren Grom • March 8, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

The ‘recovering academic’ leading Allogene to the next stage of cell therapy

Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

By Michael Gibney • March 2, 2023

Woman of the Week: Denali Therapeutics’ Cindy Dunkle

As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

By Taren Grom • March 1, 2023

Reata’s stock plummets amid sudden FDA neuro office shakeup

The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

By Karissa Waddick • Feb. 28, 2023

Who is Vivek Ramaswamy — the biotech entrepreneur turned presidential candidate?

The former CEO of Roivant, who became the face of the “anti-woke” business movement, is now running for the 2024 Republican presidential nomination. Here’s what he stands for. 

By Karissa Waddick • Feb. 27, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023

Tapping into the molecular fountain of youth

Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.

By Alexandra Pecci • Feb. 22, 2023

Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

By Taren Grom • Feb. 17, 2023

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

By Michael Gibney • Feb. 16, 2023